European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

European Consortium for the Early Treatment of Diabetic Retinopathy

Objectif

Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR. For this reason, it is reasonable to hypothesize that therapeutic strategies based on neuroprotection will be effective not only in preventing or arresting retinal neurodegeneration but also in preventing the development and progression of the early stages of DR (ie. microaneurysms and/or retinal thickness).
EUROCONDOR (European Consortium for the Early Treatment of Diabetic Retinopathy) is a solid and well balanced consortium (ophthalmologists, endocrinologists, basic researchers) which has been created in order to implement the first clinical trial using eye drops for treatment of the early stages of DR. The participants are top leaders in their field and central readings will be performed by the Coordinating Centre of the European Vision Institute Clinical Research Network (EVICR.Net).
The main objectives of the project are the following:
Primary objective: To assess whether the selected neuroprotective drugs (brimonidine and somatostatin) administered topically are able to prevent or arrest neurodegeneration, as well as the development and progression of the early stages of DR.
Secondary objectives: 1) To determine the prevalence of functional abnormalities related to neurodegeneration in those patients without or with minimal microvascular damage under ophthalmoscopic examination. 2) To compare the effectiveness of the selected drugs. 3) To evaluate the local and systemic adverse effects of the selected drugs. 4) To identify those patients most prone to progressive worsening (characterization of phenotypes and circulating biomarkers). 5) To determine the molecular mechanisms by which the selected drugs exert their beneficial effects.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

FP7-HEALTH-2011-two-stage
Voir d’autres projets de cet appel

Régime de financement

CP-FP - Small or medium-scale focused research project

Coordinateur

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Contribution de l’UE
€ 958 679,80
Adresse
PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA
08035 Barcelona
Espagne

Voir sur la carte
Région
Este Cataluña Barcelona
Type d’activité
Research Organisations
Contact administratif
Montse Giménez (Mrs.)
Liens
Coût total
Aucune donnée

Participants (17)

Partager cette page

Télécharger

Dernière mise à jour: 25 Mai 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/278040/fr

European Union, 2024